Add-on combination and maintenance treatment: Case series of five obese patients with different eating behavior

Journal of Clinical Psychopharmacology

Volumn 22, Issue 5, 2002, Pages 521-524

  Anghelescu, Ion ^a   Klawe, Christoph ^a   Szegedi, Armin ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; ANTIOBESITY AGENT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE;

ABDOMINAL DISTENSION; ADD ON THERAPY; ADULT; ANOREXIA; APHASIA; ARTICLE; BODY MASS; BORDERLINE HYPERTENSION; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FECES INCONTINENCE; FEEDING BEHAVIOR; FEMALE; HUMAN; HUNGER; MAINTENANCE THERAPY; MALE; MONOTHERAPY; OBESITY; OBSERVATION; OUTPATIENT CARE; PARESTHESIA; PRIORITY JOURNAL; QUESTIONNAIRE; RELAPSE; STEATORRHEA; TREATMENT OUTCOME; VERTIGO; XEROSTOMIA;

EID: 0036785050     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200210000-00014     Document Type: Article

References (14)

1. Willet WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999;341:427-34.
2. Visscher TL, Seidell JC. The public health impact of obesity. Annu Rev Public Health 2001;22:355-75.
3. National Institute of Diabetes and Digestive and Kidney Diseases. Overweight, obesity, and health risk. National Task Force on the Prevention and Treatment of Obesity 2000;160:898-904.
4. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352:167-72.
5. Bray GA, Tartaglia LA. Medicinal strategies in the treatment of obesity. Nature 2000;404:672-7.
6. Privitera M. Topiramate: a new antiepileptic drug. Ann Pharmacother 1997;31:1164-73.
7. Pudel V, Westenhöfer J. Fragebogen zum Eßverhalten (FEV). Göttingen: Verlag für Psychologie, Dr. C. J. Hogrefe, 1989.
8. Stunkard AJ, Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res 1985;29:71-83.
9. Wadden TA, Berkowitz RI, Womble LG, et al. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000;8:431-7.
10. York DA, Singer L, Thomas S, et al. Effect of topiramate on body weight and body composition of Osborne-Mendel rats bed a high-fat diet: alterations in hormones, neuropeptides, and uncoupling-protein mRNAs. Nutrition 2000;16:967-75.
11. Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 2000;61:368-72.
12. Davanzo P, Cantwell E, Kleiner J, et al. Cognitive changes during topiramate therapy. J Am Acad Child Adolesc Psychiatry 2001;40: 262-3.
13. Baptista T, Lacruz A, De Mendoza D, et al. Body weight gain after administration of antipsychotic drugs. Pharmacopsychiatry 2002; 35:36.
14. Anghelescu I, Klawe C, Benkert O. Orlistat in the treatment of psychopharmacologically induced weight gain. J Clin Psychopharmacol 2000;20:716-7.